MGC Pharma's cannabis epilepsy therapy CannEpil available for some UK patients
Olga Tsareva/iStock via Getty Images
- MGC Pharmaceuticals (OTCPK:MGCLF) said its epilepsy product CannEpil is now available to patients in the U.K. via Named Patient Request.
- The company noted that CannEpil is an investigational medicinal product (IMP) for patients with refractory epilepsy, also called drug-resistant epilepsy.
- The high-CBD, low-THC formulation is given via an oral mucosal solution and is currently under a clinical development program, according to the company.
- The availability in the U.K. follows the company's announcement that it is providing the product for an observational trial supported by the I am Billy Foundation.
- The company added that with this development, doctors in the U.K. listed on the General Medical Council (GMC) Specialist Register can now prescribe CannEpil.
- MGC said that CannEpil has already been prescribed to hundreds of patients in Australia and Ireland.